226 related articles for article (PubMed ID: 25037034)
21. Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial.
Esposito S; Fling J; Chokephaibulkit K; de Bruijn M; Oberye J; Zhang B; Vossen J; Heijnen E; Smolenov I
Pediatr Infect Dis J; 2020 Aug; 39(8):e185-e191. PubMed ID: 32404782
[TBL] [Abstract][Full Text] [Related]
22. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
23. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
Kumar D; Campbell P; Hoschler K; Hidalgo L; Al-Dabbagh M; Wilson L; Humar A
Transplantation; 2016 Mar; 100(3):662-9. PubMed ID: 26335915
[TBL] [Abstract][Full Text] [Related]
24. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
[TBL] [Abstract][Full Text] [Related]
25. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R
Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.
Camilloni B; Basileo M; Valente S; Nunzi E; Iorio AM
Hum Vaccin Immunother; 2015; 11(3):553-63. PubMed ID: 25714138
[TBL] [Abstract][Full Text] [Related]
27. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D
Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956
[TBL] [Abstract][Full Text] [Related]
29. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M
Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368
[TBL] [Abstract][Full Text] [Related]
30. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.
Czajka H; Unal S; Ulusoy S; Usluer G; Strus A; Sennaroglu E; Guzik J; Topeli Iskit A; Dargiewicz A; Musial D; Caylan R; Dziduch J; Eskioglu E; Hasiec B; Cwinarowiczliwa E; Belli R; Abdel-Messih IA; Beygo J; Fragapane E
J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ
Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632
[TBL] [Abstract][Full Text] [Related]
32. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
33. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
[TBL] [Abstract][Full Text] [Related]
34. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
Vesikari T; Knuf M; Wutzler P; Karvonen A; Kieninger-Baum D; Schmitt HJ; Baehner F; Borkowski A; Tsai TF; Clemens R
N Engl J Med; 2011 Oct; 365(15):1406-16. PubMed ID: 21995388
[TBL] [Abstract][Full Text] [Related]
35. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
36. MF59 adjuvant: the best insurance against influenza strain diversity.
O'Hagan DT; Rappuoli R; De Gregorio E; Tsai T; Del Giudice G
Expert Rev Vaccines; 2011 Apr; 10(4):447-62. PubMed ID: 21506643
[TBL] [Abstract][Full Text] [Related]
37. Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children - A systematic review and a meta-analysis.
Patel MM; Davis W; Beacham L; Spencer S; Campbell AP; Lafond K; Rolfes M; Levine MZ; Azziz-Baumgartner E; Thompson MG; Fry AM
Vaccine; 2020 Jan; 38(3):608-619. PubMed ID: 31735505
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.
Song JY; Cheong HJ; Tsai TF; Chang HA; Choi MJ; Jeon JH; Kang SH; Jeong EJ; Noh JY; Kim WJ
Vaccine; 2015 Aug; 33(36):4647-52. PubMed ID: 25980426
[TBL] [Abstract][Full Text] [Related]
39. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
[TBL] [Abstract][Full Text] [Related]
40. Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
Hoschler K; Andrews NJ; Faust SN; Finn A; Pollard AJ; Snape MD; Walker WT; Zambon M; Miller E
Clin Infect Dis; 2014 Jan; 58(2):181-7. PubMed ID: 24149079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
